A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects With Beta Thalassemia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: IMR-BTL-201demonstrated that while IMR-687 was generally well-tolerated, it failed to show any meaningful benefit in transfusion burden or improvement in most disease-related biomarkers. So, the sponsor has decided to discontinue this study
20 Apr 2022 This trial has been discontinued in Greece (End date: 6th April 2022)according to European Clinical Trials Database record.
05 Apr 2022 According to an Imara Inc media release, the company has decided to discontinue Ardent and Forte during the second quarter as well as the further development of tovinontrine in sickle cell disease and beta-thalassemia.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com